[go: up one dir, main page]

MX2011014025A - Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis. - Google Patents

Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis.

Info

Publication number
MX2011014025A
MX2011014025A MX2011014025A MX2011014025A MX2011014025A MX 2011014025 A MX2011014025 A MX 2011014025A MX 2011014025 A MX2011014025 A MX 2011014025A MX 2011014025 A MX2011014025 A MX 2011014025A MX 2011014025 A MX2011014025 A MX 2011014025A
Authority
MX
Mexico
Prior art keywords
iontophoresis
rotigotine
salts
acid
pharmaceutical composition
Prior art date
Application number
MX2011014025A
Other languages
English (en)
Inventor
Hans-Michael Wolff
J A Bouwstra
O W G M K Ackaert
J Eikelenboom
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of MX2011014025A publication Critical patent/MX2011014025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La presente invención se refiere a nuevas sales de 6- (propil-(2-tiofen-2-iletil)amino)tetralin-1 -oI (rotigotina), su uso como medicamento, por e'emplo para el tratamiento de trastornos del SNC como la Enfermedad de Parkinson, RLS, fibromialgia y/o depresión, en particular a través de la administración electromotriz. La presente invención se refiere a formulaciones farmacéuticas adecuadas para la iontoforesis que proporciona suministro iontoforético mejorado de rotigotina a al menos un tejido diana. Las formulaciones se caracterizan además por buena a excelente solubilidad de la sales en soluciones acuosas.
MX2011014025A 2009-06-26 2010-06-24 Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis. MX2011014025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09008401A EP2281559A1 (en) 2009-06-26 2009-06-26 Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
PCT/EP2010/003796 WO2010149363A2 (en) 2009-06-26 2010-06-24 A pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2011014025A true MX2011014025A (es) 2012-02-22

Family

ID=41314650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011014025A MX2011014025A (es) 2009-06-26 2010-06-24 Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis.

Country Status (12)

Country Link
US (2) US8754120B2 (es)
EP (2) EP2281559A1 (es)
JP (1) JP5771607B2 (es)
KR (1) KR20120092548A (es)
CN (2) CN103319453A (es)
AU (1) AU2010265087B2 (es)
BR (1) BRPI1015939A2 (es)
CA (1) CA2761427C (es)
EA (1) EA021940B1 (es)
IL (1) IL216256A0 (es)
MX (1) MX2011014025A (es)
WO (1) WO2010149363A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
PT2215072E (pt) * 2007-11-28 2015-10-14 Ucb Pharma Gmbh Forma polimórfica de rotigotina
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CA2767068C (en) 2009-12-22 2016-09-27 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
WO2015177204A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
EA202090940A1 (ru) * 2017-10-18 2020-10-30 Джованни Барко Способ и устройство для получения реактивных форм кислорода и/или азота в форме жидкого раствора или газообразной форме

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5382596A (en) 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
CN1185225C (zh) 1999-11-23 2005-01-19 阿德里斯制药公司 制备氮取代的氨基1,2,3,4－四氢化萘的改进方法
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
SI1256340T1 (en) 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1494664A2 (en) 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2009063171A1 (en) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Novel rotigotine salts
PT2215072E (pt) 2007-11-28 2015-10-14 Ucb Pharma Gmbh Forma polimórfica de rotigotina
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CA2767068C (en) 2009-12-22 2016-09-27 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Also Published As

Publication number Publication date
CN103319453A (zh) 2013-09-25
EP2445496A2 (en) 2012-05-02
JP5771607B2 (ja) 2015-09-02
EA021940B1 (ru) 2015-10-30
BRPI1015939A2 (pt) 2016-09-27
CA2761427C (en) 2016-11-22
US20140243386A1 (en) 2014-08-28
US20120101146A1 (en) 2012-04-26
WO2010149363A3 (en) 2011-03-24
JP2012530741A (ja) 2012-12-06
WO2010149363A2 (en) 2010-12-29
CN102458397A (zh) 2012-05-16
EA201101525A1 (ru) 2012-08-30
AU2010265087B2 (en) 2015-01-22
US9034914B2 (en) 2015-05-19
CA2761427A1 (en) 2010-12-29
KR20120092548A (ko) 2012-08-21
US8754120B2 (en) 2014-06-17
IL216256A0 (en) 2012-01-31
EP2281559A1 (en) 2011-02-09
AU2010265087A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
MX2011014025A (es) Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis.
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
MX2010013020A (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
MX2009010407A (es) Derivados fluorados de deferiprona.
UA106634C2 (uk) Тверда фармацевтична дозована форма
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
UA105036C2 (uk) Амінотетралінові похідні, фармацевтична композиція, яка їх містить, і їх застосування в терапії
MX2011009847A (es) Agentes antihelminticos y su uso.
MY178634A (en) Topical formulation for a jak inhibitor
PH12012502404A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2009010778A (es) Composiciones y metodos para el tratamiento de insuficiencia cardiaca.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
CL2013003057A1 (es) Composicion farmaceutica de aerosol en forma de solución acuosa para nebulización que comprende iloprost, que proporciona una dosis unica eficaz aerolizada para inhalacion de bolo en un periodo de menos de 2 minutos; kit farmacéutio, util en el tratamiento de hipertension arterial pulmonar.
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2007124358A3 (en) Pharmaceutical formulations for iontophoretic drug delivery
TW200800977A (en) A new salt

Legal Events

Date Code Title Description
FG Grant or registration